A Single Dose Study to Evaluate the Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
Status: Recruiting
Location: See all (11) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 10
Maximum Age: 17
Healthy Volunteers: f
View:
• Participants with Type 2 Diabetes Mellitus (T2DM) for at least 3 months
• Have Glycated hemoglobin (HbA1c) level of 6.5 percent (%) to 9.5% at screening
• Have a body mass index equal to or less than 45.0 kilograms per square meter (kg/m²)
• Participants are insulin naïve or have been without insulin treatment for at least 3 months prior to screening
Locations
United States
California
Children's Hospital Los Angeles
RECRUITING
Los Angeles
Georgia
Children's Healthcare of Atlanta - Center for Advanced Pediatrics
RECRUITING
Atlanta
Centricity Research Columbus Endocrinology
RECRUITING
Columbus
Massachusetts
Joslin Diabetes Center
RECRUITING
Boston
Maryland
Johns Hopkins Hospital
RECRUITING
Baltimore
Missouri
Sundance Clinical Research
NOT_YET_RECRUITING
St Louis
New York
UBMD Pediatrics
RECRUITING
Buffalo
NYU Langone
NOT_YET_RECRUITING
New York
Ohio
Cincinnati Children's Hospital Medical Center
RECRUITING
Cincinnati
Pennsylvania
Children's Hospital of Philadelphia
NOT_YET_RECRUITING
Philadelphia
Tennessee
Lifedoc Research - Lenox Park Drive
RECRUITING
Memphis
Contact Information
Primary
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
LillyTrials@Lilly.com
1-317-615-4559
Backup
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
Time Frame
Start Date: 2024-10-10
Estimated Completion Date: 2026-11
Participants
Target number of participants: 22
Treatments
Experimental: LY3209590
LY3209590 administered subcutaneously (SC).
Related Therapeutic Areas
Sponsors
Leads: Eli Lilly and Company